Monday, December 14, 2020 9:19:37 AM
New York Yankees and Duke Basketball
Recent ARVN News
- Arvinas to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer • GlobeNewswire Inc. • 04/24/2024 08:30:38 PM
- Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer • GlobeNewswire Inc. • 04/11/2024 11:00:49 AM
- Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer • GlobeNewswire Inc. • 03/18/2024 08:40:46 PM
- Arvinas to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 03/04/2024 12:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:35:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:33:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:33:04 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 09:46:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:02:59 PM
- Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/27/2024 12:00:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:06:49 PM
- Arvinas Announces Chief Financial Officer Transition • GlobeNewswire Inc. • 02/20/2024 09:05:04 PM
- Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease • GlobeNewswire Inc. • 02/20/2024 12:00:44 PM
- Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer • GlobeNewswire Inc. • 02/14/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:14:06 AM
- Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer • GlobeNewswire Inc. • 02/06/2024 11:45:00 AM
- Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference • GlobeNewswire Inc. • 02/01/2024 09:30:20 PM
- Arvinas Appoints Jared Freedberg as General Counsel • GlobeNewswire Inc. • 01/16/2024 10:01:06 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/16/2024 09:03:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:39:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:45:42 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 12/08/2023 02:16:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 12:01:32 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM